Bionexus Gene Lab's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Bionexus Gene Lab's ROI in the second quarter of 2026?
Bionexus Gene Lab Corp recorded a cumulative net loss of $-3 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -32.14%.

Within the Healthcare sector 173 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2974 to 3545.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-4.15 %	-9.58 %	-13.63 %	-18.03 %	-12.56 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	8	8	9	7	8
Return On Investment (TTM)	-32.14 %	-36.46 %	-37.76 %	-29.54 %	-35.09 %
BGLC's Overall Ranking	# 3545	# 2974	# 3253	# 2755	# 2691
Seq. Investment Change TTM	0.56 %	0.81 %	1.66 %	-6.99 %	-5.14 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-3	-3	-3	-2	-3

BGLC Company Profile >> Back to BGLC Roi Comparisons >> See Annual BGLC Return On Investment

Return On Investment BGLC's Ranking
Within:	No.
Industry	# 14
Sector	# 174
Overall	# 3545

Return On Investment Statistics
High	Average	Low
44.61 %	-10.92 %	-42.29 %
(Dec 31 2020)		(Sep 30 2023)

Financial Statements
Bionexus Gene Lab's II. Quarter Investments	$ 8 Millions	BGLC's Balance sheet
Bionexus Gene Lab's II. Quarter Income	$ 0 Millions	Quarterly BGLC's Income Statement
BGLC's Income by Division		See BGLC's Income by Division

BGLC Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	9	8	10	7	7
Y / Y Investment Growth	3.51 %	-13.82 %	43.38 %	-7.03 %	7.47 %
Net Income in Millions	-3	-2	-3	0	1
Y / Y Net Income Growth	-	-	-	-	-31.31 %
Annual Return On Investment	-34.64 %	-19.2 %	-27.22 %	-5.28 %	10.37 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Laboratories Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BGLC's Roi Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BGLC's Competitors
Subscribers only: Roi for Bionexus Gene Lab's Suppliers
Subscribers only: Return On Investment for BGLC's Customers

Other Ratios
BGLC's Roa	BGLC's Inventory Turnover Ratio	BGLC's Growth Rates	BGLC's Dividend Statistics
	BGLC's Profitability Ratios	BGLC's Asset Turnover Ratio	BGLC's Dividend Growth
BGLC's Roe	BGLC's Valuation Ratios	BGLC's Financial Strength Ratios	BGLC's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-08-17T17:18:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.